The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus), Proc R Soc Med, vol.3, pp.1-48, 1910. ,
DISCUSSION PAPER: EXPERIMENTAL AND CLINICAL IMMUNOPHARMACOLOGY DATA APPLICABLE TO CANCER IMMUNOTHERAPY, Annals of the New York Academy of Sciences, vol.277, issue.1 International, pp.467-84, 1976. ,
DOI : 10.1111/j.1749-6632.1976.tb41721.x
Recent advances in bacillus Calmette???Guerin immunotherapy in bladder cancer, Immunotherapy, vol.2, issue.4, pp.551-60, 2010. ,
DOI : 10.2217/imt.10.32
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.144, issue.5, pp.1565-70, 2011. ,
DOI : 10.1016/j.cell.2011.02.013
Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011. ,
DOI : 10.1016/j.cell.2011.02.013
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684., Journal of Clinical Oncology, vol.14, issue.1, pp.7-17, 1996. ,
DOI : 10.1200/JCO.1996.14.1.7
Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2, Annals of Surgery, vol.228, issue.3, pp.307-326, 1998. ,
DOI : 10.1097/00000658-199809000-00004
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010. ,
DOI : 10.1056/NEJMoa1003466
Oncology Meets Immunology: The Cancer-Immunity Cycle, Immunity, vol.39, issue.1, pp.1-10, 2013. ,
DOI : 10.1016/j.immuni.2013.07.012
Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies, European Journal of Cancer, vol.49, issue.14, pp.2968-71, 2013. ,
DOI : 10.1016/j.ejca.2013.07.001
Breakthrough of the year 2013, Cancer immunotherapy. Science, vol.342, issue.6165, pp.1432-1435, 2013. ,
The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, pp.252-64, 2012. ,
DOI : 10.1038/nrc3239
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proceedings of the National Academy of Sciences, vol.264, issue.5161, pp.12293-12300, 2002. ,
DOI : 10.1126/science.7513904
B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation, Proceedings of the National Academy of Sciences, vol.180, issue.1, pp.2741-2747, 2009. ,
DOI : 10.1084/jem.20022235
PD-1 and Its Ligands in Tolerance and Immunity, Annual Review of Immunology, vol.26, issue.1, pp.677-704, 2008. ,
DOI : 10.1146/annurev.immunol.26.021607.090331
On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation, Science Translational Medicine, vol.12, issue.19, pp.280-281, 2015. ,
DOI : 10.1186/1479-5876-8-71
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells, Blood, vol.111, issue.7, pp.3635-3678, 2008. ,
DOI : 10.1182/blood-2007-11-123141
Inhibitory B7-family molecules in the tumour microenvironment, Nature Reviews Immunology, vol.106, issue.6, pp.467-77, 2008. ,
DOI : 10.1038/nri2326
Tumor-associated B7- H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, vol.8, issue.8, pp.793-800, 2002. ,
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy, Cancer Cell, vol.27, issue.4, pp.450-61, 2015. ,
DOI : 10.1016/j.ccell.2015.03.001
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer, Oncogene, vol.104, issue.2, pp.306-318, 2009. ,
DOI : 10.1038/onc.2008.384
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nature Medicine, vol.8, issue.1, pp.84-92, 2007. ,
DOI : 10.1038/nm1517
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape, Science Translational Medicine, vol.27, issue.36, pp.127-164, 2012. ,
DOI : 10.1200/JCO.2009.23.4799
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells, Cancer Research, vol.74, issue.3, pp.665-74, 2014. ,
DOI : 10.1158/0008-5472.CAN-13-0992
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma, Clinical Cancer Research, vol.20, issue.13, pp.3446-57, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-2797
Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1, Clinical Cancer Research, vol.18, issue.24, pp.6580-6587, 2012. ,
DOI : 10.1158/1078-0432.CCR-12-1362
The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo, The Journal of Immunology, vol.187, issue.3, pp.1113-1122, 2011. ,
DOI : 10.4049/jimmunol.1100056
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Current Opinion in Immunology, vol.24, issue.2, pp.207-219, 2012. ,
DOI : 10.1016/j.coi.2011.12.009
Safety, Activity, and Immune Correlates of Anti???PD-1 Antibody in Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2443-54, 2012. ,
DOI : 10.1056/NEJMoa1200690
Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015. ,
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00872683
Nivolumab versus Docetaxel in Advanced Nonsquamous Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.17, pp.1627-1666, 2015. ,
DOI : 10.1056/NEJMoa1507643
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.2, pp.123-158, 2015. ,
DOI : 10.1056/NEJMoa1504627
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015. ,
DOI : 10.1056/NEJMoa1510665
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040., Journal of Clinical Oncology, vol.33, issue.18_suppl, p.2015 ,
DOI : 10.1200/jco.2015.33.18_suppl.lba101
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer, J Clin Oncol, vol.32, p.5 ,
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032, J Clin Oncol, vol.33, p.2015 ,
Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2553, 2015. ,
DOI : 10.1056/NEJMoa1503093
Pembrolizumab for the Treatment of Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.21, pp.2018-2046, 2015. ,
DOI : 10.1056/NEJMoa1501824
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet, vol.387, issue.10027, pp.1540-50, 2016. ,
DOI : 10.1016/S0140-6736(15)01281-7
Pembrolizumab (MK-3475) for advanced urothelial cancer : Updated results and biomarker analysis from KEYNOTE-012, J Clin Oncol, vol.33, p.2015 ,
MK- 3475) for patients (pts) with advanced esophageal carcinoma : Preliminary results from KEYNOTE-028, J Clin Oncol, vol.33, p.2015 ,
MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028, MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028. Eur Cancer Congr 2015 Abstr502, p.2015 ,
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, vol.372, issue.26, pp.2509-2529, 2015. ,
DOI : 10.1056/NEJMoa1500596
Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma, J Clin Oncol, 2014. ,
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.9, issue.7528, pp.563-570, 2014. ,
DOI : 10.1038/nature14011
Atezolizumab, an Anti???Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study, Journal of Clinical Oncology, vol.34, issue.8, pp.833-875, 2016. ,
DOI : 10.1200/JCO.2015.63.7421
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, The Lancet, vol.387, issue.10030, pp.1837-1883, 2016. ,
DOI : 10.1016/S0140-6736(16)00587-0
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, The Lancet, vol.387, issue.10031, pp.1909-1929, 2016. ,
DOI : 10.1016/S0140-6736(16)00561-4
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.45, issue.7528, pp.558-62, 2014. ,
DOI : 10.1038/nature13904
Safety and Activity of Anti???PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2455-65, 2012. ,
DOI : 10.1056/NEJMoa1200694
Safety and clinical activity of avelumab (MSB001078C), an anti-PD-L1 antibody, in patients with advanced ,
Avelumab (MSB001078C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy, J Clin Oncol, vol.33, p.2015 ,
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity, J Clin Oncol, vol.33, p.2015 ,
Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with nonsmall cell lung cancer (NSCLC), J Clin Oncol, vol.33, p.2015 ,
Safety and efficacy od MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort, J Clin Oncol, vol.33, p.2015 ,
Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer, J Clin Oncol, vol.34, p.2016 ,
Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028, Cancer Research, vol.75, issue.15 Supplement, pp.103-103, 2015. ,
DOI : 10.1158/1538-7445.AM2015-CT103
Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study, J Clin Oncol J Clin Oncol, vol.33, 2015. ,
Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort., Journal of Clinical Oncology, vol.33, issue.18_suppl, p.2015 ,
DOI : 10.1200/jco.2015.33.18_suppl.lba6008
MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer ,
Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 mono, J Clin Oncol, vol.33, p.2015 ,
Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR), J Clin Oncol, vol.33, p.2015 ,
Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC), Cancer Research, vol.75, issue.15 Supplement, pp.2859-2859, 2015. ,
DOI : 10.1158/1538-7445.AM2015-2859
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer, Clinical Cancer Research, vol.19, issue.5, pp.1021-1055, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-2063
Overall Survival and Long-Term Safety of Nivolumab (Anti???Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.33, issue.18, pp.2004-2016, 2015. ,
DOI : 10.1200/JCO.2014.58.3708
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1624
Treatment beyond progression with nivolumab (nivo) in patients with avdanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study, J Clin Oncol, vol.34, p.2016 ,
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Annals of Oncology, vol.27, issue.4, pp.559-74, 2016. ,
DOI : 10.1093/annonc/mdv623
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann Oncol, vol.26, issue.12, pp.2375-91, 2015. ,
Identification and management of toxicities from immune checkpointblocking drugs, Oncology, vol.28, pp.30-38, 2014. ,
Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Research, vol.75, issue.11, pp.2139-2184, 2015. ,
DOI : 10.1158/0008-5472.CAN-15-0255
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452411
Rationale for anti-OX40 cancer immunotherapy, European Journal of Cancer, vol.52, pp.50-66, 2016. ,
DOI : 10.1016/j.ejca.2015.08.021
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape, Cancer Research, vol.72, issue.4, pp.917-944, 2012. ,
DOI : 10.1158/0008-5472.CAN-11-1620
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288154
Indoleamine 2,3-Dioxygenase, The Cancer Journal, vol.16, issue.4, pp.354-363, 2010. ,
DOI : 10.1097/PPO.0b013e3181eb3343
Chapter Six -Combinatorial Cancer Immunotherapies Advances in Immunology, Tumor Immunology, vol.2016, issue.130, pp.251-77 ,
DOI : 10.1016/bs.ai.2015.12.005
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.23-34, 2015. ,
DOI : 10.1056/NEJMoa1504030
URL : http://www.zora.uzh.ch/113016/1/608_Larkin%20et%20al%20_NEJM%202015.pdf
Phase I Study of Single-Agent Anti???Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates, Journal of Clinical Oncology, vol.28, issue.19, pp.3167-75, 2010. ,
DOI : 10.1200/JCO.2009.26.7609
Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial, J Clin Oncol, 2014. ,
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, The Lancet Oncology, vol.16, issue.3, pp.257-65, 2015. ,
DOI : 10.1016/S1470-2045(15)70054-9
Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC), J Clin Oncol, vol.33, p.2015 ,
Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475, J Clin Oncol, 2014. ,
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers, PLOS ONE, vol.348, issue.6230, p.130142, 2015. ,
DOI : 10.1371/journal.pone.0130142.s001
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy, Clinical Cancer Research, vol.20, issue.19, pp.5064-74, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-3271
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.16, issue.4, pp.375-84, 2015. ,
DOI : 10.1016/S1470-2045(15)70076-8
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial, Journal of Clinical Oncology, vol.33, issue.13, pp.1430-1437, 2015. ,
DOI : 10.1200/JCO.2014.59.0703
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes, J Clin Oncol, vol.33, p.2015 ,
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL) Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001, J Clin Oncol J Clin Oncol, vol.33, issue.33, p.2015, 2015. ,
Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) ,
14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR), European Journal of Cancer, vol.51, 2015. ,
DOI : 10.1016/S0959-8049(15)30072-1
Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study, J Clin Oncol, vol.33, p.2015 ,
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC), J Clin Oncol, vol.33, p.2015 ,
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity. Eur Cancer Congr, 2015. ,
High tumoral IFN ? mRNA, PD-L1 protein, and combined IFN? mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) ,
DOI : 10.1016/s0959-8049(16)31937-2
A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV?associated head and neck (H/N) cancer, J Clin Oncol, 2014. ,
Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. Eur Cancer Congr, 2015. ,
Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC), Cancer Research, vol.75, issue.15 Supplement, pp.1310-1310, 2015. ,
DOI : 10.1158/1538-7445.AM2015-1310
Abstract LB-094: A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative:, Am Assoc Cancer Res Congr 2016 Abstr LB094 ,
DOI : 10.1158/1538-7445.AM2016-LB-094
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells, Cancer Immunology Research, vol.3, issue.12, pp.1308-1323, 2015. ,
DOI : 10.1158/2326-6066.CIR-15-0116
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy, Molecular Cancer Therapeutics, vol.14, issue.4, pp.847-56, 2015. ,
DOI : 10.1158/1535-7163.MCT-14-0983
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?, Journal of Thoracic Oncology, vol.10, issue.7, pp.985-994, 2015. ,
DOI : 10.1097/JTO.0000000000000526
Predictive biomarker testing for programmed death 1 inhibition in non-small cell lung cancer. 16th World Conf Lung Cancer, 2015. ,
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials, Pigment Cell & Melanoma Research, vol.369, issue.3, pp.245-53, 2015. ,
DOI : 10.1111/pcmr.12340
Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with nonsmall cell lung cancer (NSCLC), J Clin Oncol, vol.33, p.2015 ,
??valuation de l???expression de PD-L1 en immunohistochimie??: un biomarqueur ??mergent dans les carcinomes pulmonaires non ?? petites cellules, Annales de Pathologie, vol.36, issue.1, pp.94-102, 2016. ,
DOI : 10.1016/j.annpat.2015.11.004
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer, Cell Death and Differentiation, vol.118, issue.1, pp.15-25, 2014. ,
DOI : 10.1038/cdd.2013.67
Radiotherapy Complements Immune Checkpoint Blockade, Cancer Cell, vol.27, issue.4, pp.437-445, 2015. ,
DOI : 10.1016/j.ccell.2015.03.015
URL : http://dx.doi.org/10.1016/j.ccell.2015.03.015
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition, Clinical Cancer Research, vol.19, issue.3, pp.598-609, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-2731
Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALKrearranged non-small cell lung cancer (NSCLC), J Clin Oncol, vol.33, p.2015 ,
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Annals of Oncology, vol.27, issue.1, pp.147-53, 2016. ,
DOI : 10.1093/annonc/mdv489
Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non???Small-Cell Lung Cancer, Clinical Lung Cancer, vol.16, issue.5, pp.385-90, 2015. ,
DOI : 10.1016/j.cllc.2015.03.008
Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up, Cancer Research, vol.66, issue.7, pp.3381-3386, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-4303
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma, Cancer, vol.20, issue.10, pp.2084-91, 2005. ,
DOI : 10.1002/cncr.21470
Spatiotemporal effects on programmed death ligand 1 (PD- L1) expression and immunophenotype of non-small cell lung cancer (NSCLC). 16th World Conf Lung Cancer, p.3, 2015. ,
Abstract 2857: Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma, Cancer Research, vol.75, issue.15 Supplement, pp.2857-2857, 2015. ,
DOI : 10.1158/1538-7445.AM2015-2857
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis, European Journal of Surgical Oncology (EJSO), vol.41, issue.4, pp.450-456, 2015. ,
DOI : 10.1016/j.ejso.2015.01.020
Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients, J Clin Oncol, vol.33, 2015. ,
PD-L1 expression in NSCLC: analysis of a large early stage cohort; and concordance of expression in primary, nodes and metastasis. 16th World Conf Lung Cancer, 2015. ,
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis, J Thorac Dis, vol.7, issue.3, pp.462-70, 2015. ,
Association of POLEmutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1, J Clin Oncol, vol.33, p.2015 ,
PD-1 and PD- L1 expression in molecularly selected non-small-cell lung cancer patients, Br J Cancer, 2015. ,
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer, vol.17, issue.7 pt 2, pp.1757-66, 2010. ,
DOI : 10.1002/cncr.24899
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy, Cancer Treatment Reviews, vol.41, issue.10, pp.868-76, 2015. ,
DOI : 10.1016/j.ctrv.2015.11.001
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.15, issue.7528, pp.568-71, 2014. ,
DOI : 10.1038/nature13954
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418
18LBA PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer, Eur Cancer Congr 2015 Abstr 18LBA ,
DOI : 10.1016/S0959-8049(16)31940-2
Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma, Clinical Cancer Research, vol.17, issue.7, pp.1915-1938, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-0250
Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM), J Clin Oncol, vol.33, p.2015 ,
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature, J Clin Oncol, vol.33, p.2015 ,
Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients, J Clin Oncol, vol.33, p.2015 ,
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.105, issue.51, pp.124-132, 2015. ,
DOI : 10.1073/pnas.0810114105
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993154
Exomics and immunogenics, OncoImmunology, vol.127, issue.1, p.27817, 2014. ,
DOI : 10.1126/scitranslmed.3003689
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937193
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, vol.28, issue.11, pp.207-218, 2015. ,
DOI : 10.1093/bioinformatics/bts196
Biomarkers and surrogate end points???the challenge of statistical validation, Nature Reviews Clinical Oncology, vol.3, issue.6, pp.309-326, 2010. ,
DOI : 10.1038/nrclinonc.2010.43
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials, Journal for ImmunoTherapy of Cancer, vol.26, issue.8, p.15, 2016. ,
DOI : 10.1186/s40425-016-0118-0
URL : https://hal.archives-ouvertes.fr/hal-01440327